178 related articles for article (PubMed ID: 37900570)
1. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Cheema HA; Shafiee A; Athar MMT; Rafiei MA; Mehmannavaz A; Jafarabady K; Shahid A; Ahmad A; Ijaz SH; Dani SS; Minhas AMK; Nashwan AJ; Fudim M; Fonarow GC
Front Cardiovasc Med; 2023; 10():1273781. PubMed ID: 37900570
[TBL] [Abstract][Full Text] [Related]
2. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M; Pal R; Nair K; Mukhopadhyay S
Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
5. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
6. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
[TBL] [Abstract][Full Text] [Related]
8. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
[TBL] [Abstract][Full Text] [Related]
9. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
10. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews.
Karakasis P; Pamporis K; Stachteas P; Patoulias D; Bougioukas KI; Fragakis N
Heart Fail Rev; 2023 Sep; 28(5):1033-1051. PubMed ID: 37284930
[TBL] [Abstract][Full Text] [Related]
12. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
Cao Y; Li P; Li Y; Han Y
ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis.
Taheri S
World J Nephrol; 2023 Dec; 12(5):182-200. PubMed ID: 38230296
[TBL] [Abstract][Full Text] [Related]
19. Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.
Soleimani H; Saeedian B; Pasebani Y; Babajani N; Pashapour Yeganeh A; Bahirai P; Navid H; Amin A; Samsky MD; Nanna MG; Hosseini K
ESC Heart Fail; 2024 Apr; 11(2):637-648. PubMed ID: 38124239
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction.
De Marzo V; Savarese G; Porto I; Metra M; Ameri P
J Cardiovasc Med (Hagerstown); 2023 Aug; 24(8):537-543. PubMed ID: 37409599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
